Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3SLC6A2
The experimentally established mechanism targets of Racephedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.69 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.69 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.45 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | RGS12 | O14924 | 1/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | THPO | P40225 | 1/20 | 0.69 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pseudoephedrine SCHEMBL3079358 | 1.00 | ADRA2C (0.69) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL3079361 | 1.00 | ADRA2C (0.69) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL2081239 | 0.98 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL2081241 | 0.98 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL8017708 | 0.98 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL2323883 | 0.90 | ADRA2C (0.73) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL8728628 | 0.89 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL8728630 | 0.89 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL8862398 | 0.85 | CYP2D6 (0.96) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Ephedrine SCHEMBL1997836 | 0.85 | CYP2D6 (0.96) | ADRA2CADRA1ACHRM2RGS12GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-05-20 | — | — | US | disclosed |
| US-20190134022-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10124000-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9248126-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9216174-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140066476-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140051675-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140050778-A1 | NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND USE THEREOF | UNIVERSITY OF ROCHESTER (US) | 2014-02-20 | — | — | US | disclosed |
| US-8071617-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-7989626-B2 | Modulators of cellular adhesion | SAR code Corporation (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110124625-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124669-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20050267098-A1 | Modulators of cellular adhesion | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ADRA2C 168/4885ADRA1A 59/4885SLC6A2 3859/4885 |
| US-20140066476-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ADRA2C 168/4885ADRA1A 59/4885SLC6A2 3859/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | ADRA2C 168/4885ADRA1A 59/4885SLC6A2 3859/4885 |
| US-20140051675-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ADRA2C 168/4885ADRA1A 59/4885SLC6A2 3859/4885 |
| US-20140050778-A1 | NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND USE THEREOF | NSUN3, NSUN2, HNRNPF | ADRA2C 4693/4885ADRA1A 4591/4885SLC6A2 3995/4885 |
| US-10124000-B2 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | ADRA2C 168/4885ADRA1A 59/4885SLC6A2 3859/4885 |
| US-20050267098-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | ADRA2C 168/4885ADRA1A 59/4885SLC6A2 3859/4885 |
| US-20110124625-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | ADRA2C 168/4885ADRA1A 59/4885SLC6A2 3859/4885 |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ADRA2C 168/4885ADRA1A 59/4885SLC6A2 3859/4885 |
| US-20110124669-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | ADRA2C 168/4885ADRA1A 59/4885SLC6A2 3859/4885 |
| US-20190134022-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ADRA2C 168/4885ADRA1A 59/4885SLC6A2 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.